Shots:
- Verona Pharma to receive $40M including $25M upfront cash and $15M equity interest in Nuance Biotech, and is eligible to receive ~$179M in milestones along with royalties on net sales in Greater China (mainland China, Taiwan, Hong Kong and Macau)
- Verona Pharma granted Nuance Pharma exclusive right to develop & commercialize ensifentrine in Greater China and is currently evaluating the therapy in P-III program for COPD in US, EU & South Korea
- Nuance Pharma will be responsible for all costs related to clinical development & commercialization and plans to file a CT Application with CFDA in 2021 & starts clinical studies for COPD in Greater China thereafter
Click here to read full press release/ article | Ref: PR Newswire | Image: PR Newswire
The post Verona Pharma Signs $219M Agreement with Nuance Pharma to Develop and Commercialize Ensifentrine in Greater China first appeared on PharmaShots.
